Clinical Trial Update: Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on BEPREVE (bepotastine besilate ophthalmic solution) 1.5% for allergic conjunctivitis. The study status is listed as unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• Bepreve (bepotastine besilate)

Snippet

Sponsor: Hom, Milton M., OD, FAAO | Conditions: Allergic Conjunctivitis | Phase 4 | Status: UNKNOWN